Antiretroviral agents used by HIV-uninfected persons for prevention: Pre- And postexposure prophylaxis

Clinical Infectious Diseases

Volumn 50, Issue SUPPL. 3, 2010, Pages

  Grant, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMOPROPHYLAXIS; COST OF ILLNESS; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR;

ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PREGNANCY;

EID: 77951855176     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651479     Document Type: Review

References (55)

1. Conner EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173-1180. (Pubitemid 24331334)
2. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of motherto-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354(9181):795-802.
3. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. Diminution de la Transmission Mère-Enfant. Lancet 1999;353(9155):786-792.
4. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353(9155):781-785.
5. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 2002; 359(9313): 1178-1186.
6. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187(5):725-735. (Pubitemid 36286932)
7. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999;353(9155):773-780.
8. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure pro-phylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362(9391): 1171-1177. (Pubitemid 37255341)
9. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007(1):CD003510.
10. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS 2005; 19(16): 1865-1875.
11. European CS. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet 1991; 337:253.
12. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15(15):1951-1957.
13. Horvath T, Madi BC, luppa IM, Kennedy GE, Rutherford G, Read JS. Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev 2009(1):CD006734.
14. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIVinfected women for maternal health and interventions to reduce per-inatal HIV transmission in the United States. 29 April 2009:1-90. http: //aidsinfo.nih.gov/ContentFiles/ PerinatalGL.pdf. Accessed 28 July 2009.
15. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guide-lines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2009:1-161. http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentGL.pdf. Accessed 28 July 2009.
16. Smith DK, Grohskopf LA, Black RJ, et al.; US Department of Health and Human Services. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005;54(RR-2): 1-20.
17. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophy-laxis for HIV. J Acquir Immune Defic Syndr 2004;35(5):519-525.
18. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41(10):1507-1513. (Pubitemid 41579997)
19. Youle M, Wainberg M. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS 2003; 17:937-938.
20. PrEP Watch, http://www.prepwatch.org/trials.htm. 28 July 2009.
21. Peterson L, Taylor D, Roddy R, et al., Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007;2(5):e27. (Pubitemid 46851988)
22. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIVcoinfected patients: promises and pitfalls. Clin Infect Dis 2006; 43(7): 904-910. (Pubitemid 44435521)
23. Thio CL, Sulkowski MS, Thomas DL. Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis 2005; 41(7):1035-1040.
24. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr 2008;47(4):494-499. (Pubitemid 351366963)
25. Trial finds tenofovir gel safe for daily use and most women adhered to study regimens: results of phase II study of ARV-based microbicide presented at international meeting in India bolster interest in latest approach, http://www.mtnstopshiv.org/node/359. 28 July 2009.
26. Marx PA, Spira AI, Gettie A, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2(10): 1084-1089. (Pubitemid 26338626)
27. Sun Z, Denton PW, Estes JD, et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007;204(4):705-714. (Pubitemid 46631601)
28. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008;5(l):e16.
29. Tsai C-C, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-1199.
30. Van Rompay KKA, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonome-thoxy) propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000;74(4):1767-1774.
31. Van Rompay KKA, McChesney MB, Aguirre NL, Schmidt KA, Bis-chofberger N, Marthas ML. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001; 184(4):429-1138
32. Garcia-Lerma JG, Otten RA, Qari SH, et al., Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008;5(2):e28.
33. Garcia-Lerma G, Cong M-E, Mitchell J, et al. Prevention of rectal simian HIV transmission in macaques by intermittent pre-exposure prophylaxis with oral truvada. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Abstract 47.
34. Van Rompay KK, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy) propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000; 74(4):1767-1774.
35. Grant RM, Buchbinder S, Cates W Jr, et al. Promote HIV chemoprophylaxis research, don't prevent it. Science 2005; 309(5744):2170-2171.
36. Mills EJ, Rachlis B, Wu P, et al. Media reporting of tenofovir trials in Cambodia and Cameroon. BMC lnt Health Hum Rights 2005; 5(1):6. (Pubitemid 41430365)
37. Singh JA, Mills EJ. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med 2005; 2(9):e234.
38. Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008; 47(2):241-247. (Pubitemid 351172193)
39. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009; 50(l):77-83.
40. Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP study. J Infect Dis 2001; 183(5):707-714. (Pubitemid 32171744)
41. Skoler-Karpoff S, Ramjee G, Ahmed K, et al., Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9654): 1977-1987.
42. Karim S, Coletti A, Richardson B, et al., Safety and effectiveness of vaginal microbicides buffergel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial (48LB). In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Abstract 48LB.
43. Moss AR, Hahn JA, Perry S, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis 2004; 39(8):1190-1198. (Pubitemid 40169319)
44. Kalichman SC, Amaral CM, Stearns H, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med 2007; 22(7):1003-1006. (Pubitemid 46878598)
45. De Lalla F. Perioperative antibiotic prophylaxis: a critical review. Surg Infect (Larchmt) 2006; 7(Suppl 2):S37-S39.
46. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: The Achilles' heel of innovations in HIV prevention? BMJ 2006; 332(7541):605-607.
47. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med 2005;2(11):e298.
48. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369(9562):657-666.
49. Bailey RC, Moses S, Parker CB, et al., Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369(9562):643-656.
50. Bartholow BN, Buchbinder S, Celum C, et al. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2005; 39(1):90-101. (Pubitemid 40617024)
51. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18(5):787-792.
52. Celum C, Wald A, Hughes J, et al., Effect of aciclovir on HIV-l ac-quisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371(9630):2109-2119.
53. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retroviral 1997; 16(4):266-271. (Pubitemid 27524467)
54. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48(6):806-815.
55. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2007; 2(9):e875.